|
|
|
01.12.25 - 15:00
|
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial (GlobeNewswire EN)
|
|
|
Vancouver, Canada, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, recently announced three transformative milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100—the Company's proprietary, non-hallucinogenic, MEAI-based oral therapy targeting Alcohol Use Disorder (AUD). ...
|
|
|
|
|
|
|
|
|
24.11.25 - 14:54
|
Clearmind Medicine′s Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review (GlobeNewswire EN)
|
|
|
Vancouver, Canada, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that its independent Data and Safety Monitoring Board (DSMB) has completed a scheduled interim review of the Company's ongoing FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary, non-hallucinogenic neuroplastogen, in the treatment of Alcohol Use Disorder (AUD). Based on the encouraging top-line data from the first cohort, which demonstrated a favorable safety profile, the DSMB unanimously recommended that the clinical trial continue....
|
|
|
|
|
|
|
19.11.25 - 14:30
|
Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (The Newswire)
|
|
|
November 19, 2025 – TheNewswire - Vancouver, British Columbia, Canada - Neurothera Labs Inc. (TSXV: NTLX) (“Neurothera” or the “Company”), a clinical-stage biotech company and an wholly-own subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) has filed an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression.
The patent application results from the ongoing collaboration between Neurothera and Clearmind Medicine Inc. This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.
This new filing further expands the joint intellectual property portfolio developed through...
|
|
|
|
|
17.11.25 - 14:00
|
Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (GlobeNewswire EN)
|
|
|
Vancouver, Canada, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of an Israeli patent application for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression....
|
|
|
|
|
13.11.25 - 14:57
|
Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center (GlobeNewswire EN)
|
|
|
Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company's clinical trial, of which the first cohort treatment was successfully completed. ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.10.25 - 13:12
|
Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar (GlobeNewswire EN)
|
|
|
Vancouver, Canada, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, is proud to announce that its CEO, Dr. Adi Zuloff-Shani, will participate as a featured speaker at the upcoming “Women in Psychedelic Leadership: Driving Innovation & Governance” webinar. The event, hosted by the Psychedelic Association of Canada, is scheduled for October 29, 2025, at 9:00 AM PT/noon ET, and will be accessible online via Eventbrite....
|
|
|
27.10.25 - 14:24
|
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement (GlobeNewswire EN)
|
|
|
Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind's US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
